| Filed On | Filing |
|---|---|
| 14 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 13, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent: |
| 09 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed Best Efforts Secondary Of... |
| 16 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s board of directors to ef... |
| 11 Sep 2026 |
8-K: Other Events
As of the date of filing of this report, due to recent sales of Sunshine Biopharma Inc.’s (the “Company”) common stock under the Company’s previously disclosed at-the-market offering, the exercise price of the Company’s outstanding Serie... |
| 28 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 25, 2026, Dr. Andrew Keller, a director of Sunshine Biopharma Inc. (the “Company”), notified the Company that he will not be seeking or accepting reelection to the Board of Directors of the Company upon completion of his curren... |
| 03 Aug 2026 |
8-K: Other Events
As of the date of filing of this report, due to recent sales of Sunshine Biopharma Inc.’s (the “Company”) common stock under the Company’s previously disclosed at-the-market offering, the exercise price of the Company’s outstanding Serie... |
| 20 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Sunshine Biopharma Inc., a Colorado corporation (the “Company”), confirms its agreement (this “Agreement”) with Aegis Capital Corp. (“Sales Agent”), as follows: |
| 10 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Sunshine Biopharma inc., having a place of business at 1565 Lionel-Boulet boulevard, Varennes, Québec, J3X 1P7 |
| 29 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 28, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent: |
| 19 May 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed Best Efforts Secondary Of... |
| 09 Apr 2026 |
8-K: Results of Operations and Financial Condition
FORT LAUDERDALE, FL / ACCESSWIRE / April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a pharmaceutical company offering and developing life-saving medicines across oncology, antivirals, and ot... |
| 09 Mar 2026 |
8-K: Other Events
Dr. Steve N. Slilaty, Chief Executive Officer Sunshine Biopharma, Inc. |
| 20 Feb 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On February 18, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s board of directors to eff... |
| 05 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 5, 2026, Dr. Abderrazzak Merzouki resigned as chief operating officer of Sunshine Biopharma Inc., effective immediately. |
| 12 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On December 11, 2025, Sunshine Biopharma Inc. (the “Company”) held its annual meeting of stockholders. At the meeting, (i) Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were each el... |
| 30 Sep 2025 |
8-K: Changes in Registrant's Certifying Accountant
Effective September 24, 2025, Sunshine Biopharma Inc. (the “Company”), dismissed Bush & Associates CPA LLC (“Bush & Associates”), as its independent registered public accounting firm and retained M&K CPAS, PLLC (“M&K”) as its independent... |
| 19 May 2025 |
8-K: Results of Operations and Financial Condition
FORT LAUDERDALE, FL / ACCESSWIRE / May 15, 2025 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and ... |
| 03 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of April 2, 2025, between Sunshine Biopharma Inc., a Colorado corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their res... |
| 02 Apr 2025 |
8-K: Results of Operations and Financial Condition
FORT LAUDERDALE, FL / ACCESSWIRE / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and... |
| 15 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
THIS AGREEMENT is entered into on this 1st day of January, 2025: |
Loading...